The optimized drug delivery systems of treating cancer bone metastatic osteolysis with nanomaterials

Cheng, Xi; Wei, Jinrong; Ge, Qi; Xing, Danlei; Zhou, Xuefeng; Qian, Yunzhu; Jiang, Guoqin

doi:10.1080/10717544.2020.1856225

Cited by 27 publications

(16 citation statements)

References 155 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Certain patients will experience worry, despair, and other bad feelings as a result of the pain being aggravated. Patients' pain complaints improved dramatically after bisphosphonate medication, which may enhance patients' adherence to treatment [ 25 ].…”

Section: Discussionmentioning

confidence: 99%

Analysis of the Mechanism and Safety of Bisphosphonates in Patients with Lung Cancer and Bone Metastases

Zhang

Gong

2021

Computational and Mathematical Methods in Medicine

View full text Add to dashboard Cite

Objective. To explore the mechanism and safety of bisphosphonates in patients with lung cancer and bone metastases. Method. A total of 104 patients with lung cancer and bone metastases in our hospital were selected and randomly divided into two groups: control group ( n = 54 ) and research group ( n = 50 ). Chemotherapy was given to the control group, and the research group was treated with bisphosphonate drugs. The quality of life, HAMA, HAMD score, VAS score, treatment effect, serum calcium and KPS score, inflammatory factor levels, and immune function were compared between the two groups. Result. The quality of life in both groups was significantly increased ( P < 0.05 ). The HAMA and HAMD scores of the research group decreased significantly than those of the control group after treatment ( P < 0.05 ). The VAS scores of the two groups were significantly reduced ( P < 0.05 ). The effective rates of treatment in the control group and the research group were 81.5% and 96.0%, respectively. Serum calcium was significantly decreased, and KPS score was significantly increased at weeks 1 and 6 after treatment, and the change was more obvious in the research group ( P < 0.05 ). The levels of inflammatory factors in the two groups were significantly reduced, and the immune indicators were significantly increased. Conclusion. Bisphosphonates have good effect on patients with lung cancer and bone metastases, which can improve anxiety and depression, reduce pain score, improve serum calcium level and immune function, and reduce inflammatory response. Therefore, bisphosphonate drug therapy is worth widely used.

show abstract

Section: Discussionmentioning

confidence: 99%

Analysis of the Mechanism and Safety of Bisphosphonates in Patients with Lung Cancer and Bone Metastases

Zhang

Gong

2021

Computational and Mathematical Methods in Medicine

View full text Add to dashboard Cite

show abstract

“…Hematological cancers are associated with bone loss and fracture of vertebrae and long bone. Breast and lung cancer are frequently metastasized to bone and cause osteolysis (51, 52). Cancer/cancer metastasis-induced bone loss-mediated fracture is a serious clinical problem.…”

Section: Discussionmentioning

confidence: 99%

MicroRNA-155 regulates osteogenesis and bone mass phenotype via targeting S1PR1 gene

Zheng

et al. 2022

Preprint

View full text Add to dashboard Cite

MicroRNA-155 (miR155) is overexpressed in various inflammatory diseases and cancer, in which bone resorption and osteolysis are frequently observed. However, the role of miR155 on osteogenesis and bone mass phenotype is still unknown. Here, we report a low bone mass phenotype in the long bone of miR155-Tg mice compared with control mice. In contrast, miR155-KO mice showed a high bone mass phenotype. miR155-KO mice showed robust bone regeneration in the ectopic and orthotopic model, but miR155-Tg mice showed compromised bone regeneration compared with the control mice. Similarly, the osteogenic differentiation potential of bone marrow stromal stem cells (BMSCs) from miR155-KO mice was robust and miR155-Tg was compromised compared with that of control mice. Moreover, miR155 knockdown in BMSCs from control mice showed higher osteogenic differentiation potential, supporting the results from miR155-KO mice. TargetScan analysis predicted S1PR1 as a target gene of miR155, which was further confirmed by luciferase assay and miR155 knockdown. S1PR1 overexpression in BMSCs robustly promoted osteogenic differentiation without affecting cell viability and proliferation. Thus, miR155 showed a catabolic effect on osteogenesis and bone mass phenotype via interaction with the S1PR1 gene, suggesting inhibition of miR155 as a potential strategy for bone regeneration and bone defect healing.

show abstract

“…It has been shown to significantly reduce the risk of skeletalrelated events, with superior performance to zoledronic acid (a drug from the class of bisphosphonates) [95,116]. However, unlike bisphosphonates, denosumab cannot accumulate in the bone, reversing its effect after treatment discontinuation [33,36].…”

Section: Carried Agentsmentioning

confidence: 99%

Recent Advances in the Treatment of Bone Metastases and Primary Bone Tumors: An Up-to-Date Review

Bădilă

Rădulescu

Niculescu

et al. 2021

Cancers

View full text Add to dashboard Cite

In the last decades, the treatment of primary and secondary bone tumors has faced a slow-down in its development, being mainly based on chemotherapy, radiotherapy, and surgical interventions. However, these conventional therapeutic strategies present a series of disadvantages (e.g., multidrug resistance, tumor recurrence, severe side effects, formation of large bone defects), which limit their application and efficacy. In recent years, these procedures were combined with several adjuvant therapies, with different degrees of success. To overcome the drawbacks of current therapies and improve treatment outcomes, other strategies started being investigated, like carrier-mediated drug delivery, bone substitutes for repairing bone defects, and multifunctional scaffolds with bone tissue regeneration and antitumor properties. Thus, this paper aims to present the types of bone tumors and their current treatment approaches, further focusing on the recent advances in new therapeutic alternatives.

show abstract

The optimized drug delivery systems of treating cancer bone metastatic osteolysis with nanomaterials

Cited by 27 publications

References 155 publications

Analysis of the Mechanism and Safety of Bisphosphonates in Patients with Lung Cancer and Bone Metastases

Analysis of the Mechanism and Safety of Bisphosphonates in Patients with Lung Cancer and Bone Metastases

MicroRNA-155 regulates osteogenesis and bone mass phenotype via targeting S1PR1 gene

Recent Advances in the Treatment of Bone Metastases and Primary Bone Tumors: An Up-to-Date Review

Contact Info

Product

Resources

About